查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1818080

全球抗癌药物市场：预测（至 2032 年）－按药物类别、治疗类型、癌症类型、剂型、通路和地区进行分析

Oncology Drugs Market Forecasts to 2032 - Global Analysis By Drug Class, Therapy Type, Cancer Type, Dosage Form, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球抗癌药物市场预计在 2025 年达到 2,589.8 亿美元，到 2032 年将达到 6,207 亿美元，预测期内的复合年增长率为 13.3%。

抗癌药物是透过清除恶性细胞、抑制其发展和预防转移来对抗各种癌症的专门药物。这类药物包括化疗、免疫疗法、荷尔蒙疗法和标靶治疗。其主要目标是延长患者的生存期、缓解症状并改善生活品质。抗癌药物在改善癌症治疗患者的生存期、控制症状和提高生活品质方面发挥着重要作用。

根据诺华公司2020年发布的年度报告，抗癌药物部门的成长率较2019年放缓，为2.4%。

标靶治疗需求不断增长

由于标靶治疗的应用日益广泛，抗癌药物正在经历强劲增长。与传统治疗相比，标靶治疗具有更高的疗效和更少的副作用。这些治疗方法旨在抑制参与癌症进展的特定分子，从而实现更精确和个人化的治疗方法。癌症发病率的上升和诊断能力的提高正在推动对这些先进疗法的需求。製药公司正在大力投资研发针对多种癌症类型的新型标靶药物。此外，监管机构正在简化突破性治疗方法的核准途径，进一步加速了市场发展势头。随着临床医师和患者意识的提高，标靶治疗正成为现代肿瘤治疗的核心部分。

严格的监管流程

药物开发商必须满足严格的临床试验要求、安全性评估和上市后监管要求。这些流程往往会延迟产品上市并增加开发成本，尤其对于规模较小的生技公司。全球监管标准的协调仍然是一项挑战，使得国际市场准入更加复杂。此外，数据透明度和患者知情同意的合规框架不断发展，也带来了沉重的行政负担。因此，许多公司采取了谨慎的策略，选择分阶段试验和区域推广来降低风险。

精准医疗和个人化治疗

随着治疗方案越来越贴合个别基因特征，精准医疗的转变正为肿瘤学开闢新的成长途径。基因组学、生物标记识别和伴随诊断的进步使得更精准地标靶化癌细胞成为可能。这种方法在增强治疗效果的同时，最大限度地减少了副作用，对医护人员和患者都极具吸引力。政府和医疗体係也透过资金投入和基础设施升级来支持精准肿瘤学。随着个人化医疗成为主流，它有望重新定义癌症治疗模式，并推动市场持续扩张。

专利到期和生物相似药竞争

当重磅抗癌学名药和生物相似药便会进入市场，侵蚀原厂公司的收益。虽然这些替代方案具有成本效益，但它们也增加了定价压力并削弱了品牌忠诚度。生物相似药的监管核准正在简化，加速了其在主要市场的普及。此外，支付系统越来越倾向于生物相似药以降低医疗成本，这进一步挑战了品牌药的销售。如果没有持续的创新和生命週期管理，现有企业就有可能将市场份额拱手让给更敏捷的竞争对手。

COVID-19的影响

COVID-19疫情扰乱了肿瘤科诊疗流程，延误了诊断、治疗和临床试验。封锁措施以及为应对疫情而进行的资源重新分配，给肿瘤科室带来了压力，并减少了患者的就诊机会。然而，这场危机加速了数位医疗的普及，包括远距肿瘤诊疗和远端监控解决方案。製药公司透过数位化临床实验通讯协定并利用虚拟平台与病人参与，适应了这种变化。供应链中断暂时影响了药品供应，并促使企业采取多元化策略。疫情过后，重点已转向建构具有韧性的肿瘤诊疗系统，以抵御未来的中断，同时维持诊疗的连续性。

预测期内标靶治疗药物市场规模预计将达到最大

标靶治疗领域预计将在预测期内占据最大的市场份额，这得益于其卓越的疗效和特异性。由于毒性降低和患者预后改善，这些药物正逐渐成为传统化疗的首选。越来越多的临床证据和监管支持正在推动标靶治疗在多种癌症类型中更广泛的应用。製药公司正优先考虑该领域的产品线开发，目前已有多种药物处于后期临床试验阶段。生物标记和伴随诊断的整合正在提高治疗精准度，并支持其广泛应用。标靶治疗成为标准治疗方案，其很可能在标靶治疗治疗领域占据主导地位。

预计线上药局市场在预测期内将以最高的复合年增长率成长

预计线上药局领域将在预测期内实现最高成长率，这得益于消费者对数位医疗解决方案日益增长的偏好。宅配的便利性，尤其是在慢性癌症治疗领域，正在推动线上药局的普及。新冠疫情加速了医药电商化进程，越来越多的抗癌药物可以透过安全平台取得。监管机构正在更新相关框架，以支援专科药物的安全线上配药。製药公司与数位医疗服务提供者之间的伙伴关係正在扩大药局的可及性，并提高患者的依从性。随着数位基础设施的加强，线上药局有望成为肿瘤领域的关键分销管道。

比最大的地区

由于癌症发病率上升和医疗基础设施不断扩张，预计亚太地区将在预测期内占据最大市场份额。中国、印度和日本等国正大力投资肿瘤学研究、治疗中心和药物供应。政府津贴癌症治疗和改善早期检测的措施正在推动需求成长。快速的都市化和生活方式的改变导致癌症发病率上升，并刺激了药品消费的增长。本地生产和有利的监管改革正在吸引全球参与者进入该地区。随着认知度和价格分布的提高，亚太地区预计将在抗癌药物市场保持主导地位。

复合年增长率最高的地区：

由于强大的创新管道和支持性的报销政策，预计北美地区在预测期内的复合年增长率最高。美国和加拿大在精准肿瘤学研究方面处于领先地位，基因组检测和标靶治疗被广泛采用。联邦资金和私人投资正在推动免疫肿瘤学和细胞疗法的研发。 FDA 等监管机构正在简化突破性抗癌药物的核准流程。人工智慧和巨量资料在癌症研究中的整合正在加速药物研发和个人化治疗。

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

第五章全球抗癌药物市场（依药物类别）

  • 细胞毒性药物
  • 标靶治疗药物
  • 荷尔蒙疗法药物
  • 免疫疗法
  • 其他药物类别

第六章全球抗癌药物市场依治疗类型

  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 联合治疗
  • 荷尔蒙疗法

第七章全球抗癌药物市场（依癌症类型）

  • 肺癌
  • 膀胱癌
  • 乳癌
  • 甲状腺癌
  • 大肠直肠癌
  • 子宫颈癌
  • 摄护腺癌
  • 多发性骨髓瘤
  • 胃癌
  • 肝癌
  • 其他罕见癌症

第八章全球抗癌药物市场（按剂型）

  • 固体的
  • 液体
  • 注射

9. 全球抗癌药物市场（依分销管道）

  • 医院药房
  • 专科诊所
  • 零售药局
  • 网路药局

第 10 章全球抗癌药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Merck & Co.
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • AstraZeneca
  • Daiichi Sankyo
  • Johnson & Johnson
  • Sanofi
  • Roche
  • AbbVie
  • Pfizer
  • Astellas Pharma
  • Novartis
  • Amgen
  • Eli Lilly
Product Code: SMRC31043

According to Stratistics MRC, the Global Oncology Drugs Market is accounted for $258.98 billion in 2025 and is expected to reach $620.70 billion by 2032 growing at a CAGR of 13.3% during the forecast period. Oncology drugs are specialized medicines created to combat various forms of cancer by eliminating malignant cells, controlling their development, or blocking their metastasis. This category covers chemotherapy, immunotherapy, hormone therapy, and targeted treatments. Their primary purpose is to extend patient survival, ease symptoms, and improve quality of life. Oncology drugs play a crucial role in improving patient survival rates, managing symptoms, and enhancing quality of life for individuals undergoing cancer treatment.

According to the annual report of Novartis AG published in 2020, the oncology drugs segment witnessed a slow growth of 2.4% as compared to 2019.

Market Dynamics:

Driver:

Growing demand for targeted therapies

The oncology drugs is witnessing robust growth due to increasing adoption of targeted therapies that offer higher efficacy and fewer side effects compared to traditional treatments. These therapies are designed to interfere with specific molecules involved in cancer progression, making them more precise and personalized. Rising cancer prevalence and improved diagnostic capabilities are accelerating demand for such advanced treatments. Pharmaceutical companies are investing heavily in R&D to develop novel targeted agents across multiple cancer types. Additionally, regulatory bodies are streamlining approval pathways for breakthrough therapies, further boosting market momentum. As awareness grows among clinicians and patients, targeted therapies are becoming central to modern oncology care.

Restraint:

Stringent regulatory processes

Drug developers must navigate rigorous clinical trial requirements, safety evaluations, and post-marketing surveillance mandates. These processes often delay product launches and increase development costs, especially for smaller biotech firms. Harmonizing global regulatory standards remains a challenge, complicating international market entry. Moreover, evolving compliance frameworks around data transparency and patient consent add layers of administrative burden. As a result, many companies adopt cautious strategies, opting for phased trials and regional rollouts to mitigate risk.

Opportunity:

Precision medicine and personalized therapies

The shift toward precision medicine is unlocking new growth avenues in oncology, as treatments are increasingly tailored to individual genetic profiles. Advances in genomics, biomarker identification, and companion diagnostics are enabling more accurate targeting of cancer cells. This approach enhances treatment outcomes while minimizing adverse effects, making it highly attractive to both providers and patients. Governments and healthcare systems are also supporting precision oncology through funding and infrastructure upgrades. As personalized therapies become mainstream, they are expected to redefine cancer treatment paradigms and drive sustained market expansion.

Threat:

Patent expirations and biosimilar competition

As patents on blockbuster cancer drugs expire, generic and biosimilar versions enter the market, eroding revenue for originator companies. These alternatives, while cost-effective, intensify pricing pressure and reduce brand loyalty. Regulatory approvals for biosimilars are becoming more streamlined, accelerating their adoption across key markets. Additionally, payer systems are increasingly favouring biosimilars to reduce healthcare costs, further challenging branded drug sales. Without continuous innovation and lifecycle management, established players risk losing market share to agile competitors.

Covid-19 Impact

The COVID-19 pandemic disrupted oncology care pathways, delaying diagnoses, treatments, and clinical trials. Lockdowns and resource reallocation toward pandemic response strained oncology departments and reduced patient access. However, the crisis also accelerated digital health adoption, including tele-oncology and remote monitoring solutions. Pharma companies adapted by digitizing trial protocols and leveraging virtual platforms for patient engagement. Supply chain interruptions temporarily affected drug availability, prompting diversification strategies. Post-pandemic, the focus has shifted toward building resilient oncology systems that can withstand future disruptions while maintaining continuity of care.

The targeted therapy drugs segment is expected to be the largest during the forecast period

The targeted therapy drugs segment is expected to account for the largest market share during the forecast period, driven by their superior efficacy and specificity. These drugs are increasingly preferred over conventional chemotherapy due to reduced toxicity and better patient outcomes. Growing clinical evidence and regulatory support are encouraging broader adoption across multiple cancer types. Pharmaceutical firms are prioritizing pipeline development in this segment, with numerous agents in late-stage trials. Integration of biomarkers and companion diagnostics is enhancing treatment precision and boosting uptake. As targeted therapies become standard of care, they will continue to dominate the oncology drug landscape.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, due to rising consumer preference for digital healthcare solutions. The convenience of home delivery, especially for chronic cancer treatments, is driving adoption. COVID-19 accelerated the shift toward e-commerce in pharmaceuticals, with oncology drugs increasingly available through secure platforms. Regulatory bodies are updating frameworks to support safe online dispensing of specialty medications. Partnerships between pharma companies and digital health providers are expanding access and improving patient adherence. As digital infrastructure strengthens, online pharmacies are poised to become a key distribution channel in oncology.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cancer incidence and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology research, treatment centres, and drug accessibility. Government initiatives to subsidize cancer care and improve early detection are boosting demand. Rapid urbanization and lifestyle changes are contributing to higher cancer prevalence, prompting increased pharmaceutical consumption. Local manufacturing and favourable regulatory reforms are attracting global players to the region. As awareness and affordability improve, Asia Pacific will remain a dominant force in the oncology drugs market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong innovation pipelines and supportive reimbursement policies. The U.S. and Canada are leading in precision oncology, with widespread adoption of genomic testing and targeted therapies. Federal funding and private investment are fueling R&D in immuno-oncology and cell-based treatments. Regulatory agencies like the FDA are streamlining approval processes for breakthrough cancer drugs. Integration of AI and big data in oncology research is accelerating drug discovery and personalized care.

Key players in the market

Some of the key players profiled in the Oncology Drugs Market include Merck & Co., Gilead Sciences, Bristol-Myers Squibb, Takeda Pharmaceutical, AstraZeneca, Daiichi Sankyo, Johnson & Johnson, Sanofi, Roche, AbbVie, Pfizer, Astellas Pharma, Novartis, Amgen, and Eli Lilly.

Key Developments:

In September 2025, Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief to deliver lenacapavir Gilead's twice-yearly injectable HIV-1 capsid inhibitor for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance access to lenacapavir for PrEP for up to two million people over three years in countries supported by both organizations.

In July 2025, Merck and Verona Pharma plc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

Drug Classes Covered:

  • Cytotoxic Drugs
  • Targeted Therapy Drugs
  • Hormonal Therapy Drugs
  • Immunotherapy Drugs
  • Other Drug Classes

Therapy Types Covered:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapies
  • Hormonal Therapy

Cancer Types Covered:

  • Lung Cancer
  • Bladder Cancer
  • Breast Cancer
  • Thyroid Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Prostate Cancer
  • Multiple Myeloma
  • Stomach Cancer
  • Liver Cancer
  • Other Rare Cancers

Dosage Forms Covered:

  • Solid
  • Liquid
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Oncology Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Cytotoxic Drugs
  • 5.3 Targeted Therapy Drugs
  • 5.4 Hormonal Therapy Drugs
  • 5.5 Immunotherapy Drugs
  • 5.6 Other Drug Classes

6 Global Oncology Drugs Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Targeted Therapy
  • 6.4 Immunotherapy
  • 6.5 Combination Therapies
  • 6.6 Hormonal Therapy

7 Global Oncology Drugs Market, By Cancer Type

  • 7.1 Introduction
  • 7.2 Lung Cancer
  • 7.3 Bladder Cancer
  • 7.4 Breast Cancer
  • 7.5 Thyroid Cancer
  • 7.6 Colorectal Cancer
  • 7.7 Cervical Cancer
  • 7.8 Prostate Cancer
  • 7.9 Multiple Myeloma
  • 7.10 Stomach Cancer
  • 7.11 Liver Cancer
  • 7.12 Other Rare Cancers

8 Global Oncology Drugs Market, By Dosage Form

  • 8.1 Introduction
  • 8.2 Solid
  • 8.3 Liquid
  • 8.4 Injectable

9 Global Oncology Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Specialty Clinics
  • 9.4 Retail Pharmacies
  • 9.5 Online Pharmacies

10 Global Oncology Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Merck & Co.
  • 12.2 Gilead Sciences
  • 12.3 Bristol-Myers Squibb
  • 12.4 Takeda Pharmaceutical
  • 12.5 AstraZeneca
  • 12.6 Daiichi Sankyo
  • 12.7 Johnson & Johnson
  • 12.8 Sanofi
  • 12.9 Roche
  • 12.10 AbbVie
  • 12.11 Pfizer
  • 12.12 Astellas Pharma
  • 12.12 Novartis
  • 12.14 Amgen
  • 12.15 Eli Lilly

List of Tables

  • Table 1 Global Oncology Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Oncology Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Oncology Drugs Market Outlook, By Cytotoxic Drugs (2024-2032) ($MN)
  • Table 4 Global Oncology Drugs Market Outlook, By Targeted Therapy Drugs (2024-2032) ($MN)
  • Table 5 Global Oncology Drugs Market Outlook, By Hormonal Therapy Drugs (2024-2032) ($MN)
  • Table 6 Global Oncology Drugs Market Outlook, By Immunotherapy Drugs (2024-2032) ($MN)
  • Table 7 Global Oncology Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 8 Global Oncology Drugs Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 9 Global Oncology Drugs Market Outlook, By Chemotherapy (2024-2032) ($MN)
  • Table 10 Global Oncology Drugs Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 11 Global Oncology Drugs Market Outlook, By Immunotherapy (2024-2032) ($MN)
  • Table 12 Global Oncology Drugs Market Outlook, By Combination Therapies (2024-2032) ($MN)
  • Table 13 Global Oncology Drugs Market Outlook, By Hormonal Therapy (2024-2032) ($MN)
  • Table 14 Global Oncology Drugs Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 15 Global Oncology Drugs Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 16 Global Oncology Drugs Market Outlook, By Bladder Cancer (2024-2032) ($MN)
  • Table 17 Global Oncology Drugs Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 18 Global Oncology Drugs Market Outlook, By Thyroid Cancer (2024-2032) ($MN)
  • Table 19 Global Oncology Drugs Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 20 Global Oncology Drugs Market Outlook, By Cervical Cancer (2024-2032) ($MN)
  • Table 21 Global Oncology Drugs Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 22 Global Oncology Drugs Market Outlook, By Multiple Myeloma (2024-2032) ($MN)
  • Table 23 Global Oncology Drugs Market Outlook, By Stomach Cancer (2024-2032) ($MN)
  • Table 24 Global Oncology Drugs Market Outlook, By Liver Cancer (2024-2032) ($MN)
  • Table 25 Global Oncology Drugs Market Outlook, By Other Rare Cancers (2024-2032) ($MN)
  • Table 26 Global Oncology Drugs Market Outlook, By Dosage Form (2024-2032) ($MN)
  • Table 27 Global Oncology Drugs Market Outlook, By Solid (2024-2032) ($MN)
  • Table 28 Global Oncology Drugs Market Outlook, By Liquid (2024-2032) ($MN)
  • Table 29 Global Oncology Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 30 Global Oncology Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 31 Global Oncology Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 32 Global Oncology Drugs Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 33 Global Oncology Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 34 Global Oncology Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.